Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. J who wrote (1117)	5/29/1998 10:37:00 AM
From: Andreas Helke	Read Replies (1) \| Respond to of 2135

If you have big positions in other cancer biotechs you can barely afford not to own EntreMed. You have to hedge the possibility that your other cancer biotechs make much less money than expected because EntreMeds drug candidates turn out to be too successful to leave much market to other drugs. This is the major reason why I keep my shares. I bought below $14 and therefore still have a profit of more than 100% in less than 1/2 year. If more people recognize that they need EntreMed shares as a hedge the price could go up seriously despite of the fact that EntreMed currently has a pretty high market cap for a company in its state of development. If you don't need EntreMed as a hedge the best idea is probably to simply stay away from this stock because its price movement is totally unpredictable. Andreas